CY1105915T1 - Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar - Google Patents

Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar

Info

Publication number
CY1105915T1
CY1105915T1 CY20071100032T CY071100032T CY1105915T1 CY 1105915 T1 CY1105915 T1 CY 1105915T1 CY 20071100032 T CY20071100032 T CY 20071100032T CY 071100032 T CY071100032 T CY 071100032T CY 1105915 T1 CY1105915 T1 CY 1105915T1
Authority
CY
Cyprus
Prior art keywords
ppar
related diseases
treatment
thiazole derivatives
thiazole
Prior art date
Application number
CY20071100032T
Other languages
Greek (el)
English (en)
Inventor
Rodolfo Cadilla
Romain Luc Marie Gosmini
Millard Hurst Lambert, Iii
Michael Lawrence Sierra
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of CY1105915T1 publication Critical patent/CY1105915T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20071100032T 2000-12-20 2007-01-10 Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar CY1105915T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0031107.6A GB0031107D0 (en) 2000-12-20 2000-12-20 Chemical compounds
PCT/US2001/049230 WO2002062774A1 (en) 2000-12-20 2001-12-19 Thiazole derivatives for treating ppar related disorders

Publications (1)

Publication Number Publication Date
CY1105915T1 true CY1105915T1 (el) 2011-04-06

Family

ID=9905492

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100032T CY1105915T1 (el) 2000-12-20 2007-01-10 Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar

Country Status (27)

Country Link
EP (1) EP1343773B1 (enExample)
JP (1) JP4209681B2 (enExample)
KR (1) KR100815022B1 (enExample)
CN (1) CN1252057C (enExample)
AR (1) AR035522A1 (enExample)
AT (1) ATE344253T1 (enExample)
AU (1) AU2002246713B2 (enExample)
BR (1) BR0116370A (enExample)
CA (1) CA2432188A1 (enExample)
CY (1) CY1105915T1 (enExample)
CZ (1) CZ20031737A3 (enExample)
DE (1) DE60124302T2 (enExample)
DK (1) DK1343773T3 (enExample)
ES (1) ES2274914T3 (enExample)
GB (1) GB0031107D0 (enExample)
HU (1) HUP0400837A3 (enExample)
IL (2) IL156436A0 (enExample)
MX (1) MXPA03005699A (enExample)
MY (1) MY136685A (enExample)
NO (1) NO20032801L (enExample)
NZ (1) NZ526543A (enExample)
PL (1) PL365797A1 (enExample)
PT (1) PT1343773E (enExample)
SI (1) SI1343773T1 (enExample)
TW (1) TWI292759B (enExample)
WO (1) WO2002062774A1 (enExample)
ZA (1) ZA200304679B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
EP1295875A4 (en) 2000-05-26 2004-05-06 Nippon Shinyaku Co Ltd HETEROCYCLIC COMPOUNDS
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
HRP20040098B1 (en) * 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
ES2316736T3 (es) 2002-02-25 2009-04-16 Eli Lilly And Company Moduladores de receptores activados por proliferador de peroxisoma.
JP2005529077A (ja) 2002-02-25 2005-09-29 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体調節物質
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
JP2006527175A (ja) * 2003-06-06 2006-11-30 エフ.ホフマン−ラ ロシュ アーゲー アニリン誘導体
CA2530452C (en) 2003-07-02 2011-07-26 F. Hoffmann-La Roche Ag Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators
CA2539446C (en) 2003-09-19 2013-12-03 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1841748B1 (en) * 2004-12-31 2011-12-28 Seoul National University Industry Foundation Organoselenium containing compounds and their use
WO2006091047A1 (en) 2005-02-25 2006-08-31 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
US20090054493A1 (en) * 2005-02-25 2009-02-26 Heonjoong Kang Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
WO2008066356A1 (en) 2006-12-02 2008-06-05 Seoul National University Industry Foundation Aryl compounds as ppar ligands and their use
US8236831B2 (en) 2007-01-08 2012-08-07 Seoul National University Industry Foundation Thiazole compound (as PPARδ) ligand and pharmaceutical, cosmetic and health food comprised thereof
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2205548A1 (en) 2007-10-10 2010-07-14 Amgen, Inc Substituted biphenyl gpr40 modulators
CA2716352C (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
CA2789458A1 (en) * 2010-02-25 2011-09-01 Heonjoong Kang Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4623486A (en) * 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano

Also Published As

Publication number Publication date
ZA200304679B (en) 2004-10-04
MY136685A (en) 2008-11-28
EP1343773A1 (en) 2003-09-17
NO20032801L (no) 2003-08-04
ES2274914T3 (es) 2007-06-01
SI1343773T1 (sl) 2007-04-30
IL156436A0 (en) 2004-01-04
KR100815022B1 (ko) 2008-03-18
IL156436A (en) 2008-06-05
CN1252057C (zh) 2006-04-19
DK1343773T3 (da) 2007-02-05
WO2002062774A1 (en) 2002-08-15
NZ526543A (en) 2004-11-26
HK1059925A1 (en) 2004-07-23
HUP0400837A3 (en) 2007-11-28
HUP0400837A2 (hu) 2004-08-30
BR0116370A (pt) 2003-12-09
DE60124302T2 (de) 2007-05-03
JP4209681B2 (ja) 2009-01-14
CA2432188A1 (en) 2002-08-15
GB0031107D0 (en) 2001-01-31
TWI292759B (en) 2008-01-21
AU2002246713B2 (en) 2004-09-09
NO20032801D0 (no) 2003-06-19
JP2004518702A (ja) 2004-06-24
PL365797A1 (en) 2005-01-10
AR035522A1 (es) 2004-06-02
CN1527822A (zh) 2004-09-08
DE60124302D1 (de) 2006-12-14
ATE344253T1 (de) 2006-11-15
PT1343773E (pt) 2007-02-28
CZ20031737A3 (cs) 2003-10-15
EP1343773B1 (en) 2006-11-02
KR20030072571A (ko) 2003-09-15
MXPA03005699A (es) 2003-10-06

Similar Documents

Publication Publication Date Title
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
EA200001102A1 (ru) Способ синтеза ингибиторов сох-2 (циклооксигеназы-2)
NO20030374D0 (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1110104T1 (el) Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων
NO20041493L (no) Kjemiske forbindelser.
EA200100772A1 (ru) Бензогетероциклы и их применение в качестве мек ингибиторов
DK1200418T3 (da) Nematodicide trifluorbutener
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
DK1163208T3 (da) Caspaseinhibitorer og anvendelser deraf
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
EA200600330A1 (ru) Замещённые имидазопиримидины для предупреждения и лечения рака
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE223376T1 (de) Bisarylcyclobutenderivate als cyclooxygenasehemmer
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
YU53998A (en) Process for making phenyl heterocycles useful as cox-2 inhibitors
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen